Pacer Advisors Inc. Has $16.99 Million Stock Position in Lantheus Holdings, Inc. $LNTH

Pacer Advisors Inc. trimmed its holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 39.5% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 255,293 shares of the medical equipment provider’s stock after selling 166,887 shares during the quarter. Pacer Advisors Inc. owned 0.38% of Lantheus worth $16,990,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also modified their holdings of the stock. Smartleaf Asset Management LLC lifted its stake in shares of Lantheus by 63.3% in the fourth quarter. Smartleaf Asset Management LLC now owns 508 shares of the medical equipment provider’s stock valued at $34,000 after buying an additional 197 shares during the period. Blue Trust Inc. raised its holdings in Lantheus by 30.3% in the 4th quarter. Blue Trust Inc. now owns 990 shares of the medical equipment provider’s stock valued at $66,000 after acquiring an additional 230 shares in the last quarter. Vident Advisory LLC raised its holdings in Lantheus by 0.5% in the 4th quarter. Vident Advisory LLC now owns 44,763 shares of the medical equipment provider’s stock valued at $2,979,000 after acquiring an additional 230 shares in the last quarter. Farther Finance Advisors LLC raised its holdings in Lantheus by 71.4% in the 4th quarter. Farther Finance Advisors LLC now owns 660 shares of the medical equipment provider’s stock valued at $44,000 after acquiring an additional 275 shares in the last quarter. Finally, Resona Asset Management Co. Ltd. lifted its position in shares of Lantheus by 35.7% in the 4th quarter. Resona Asset Management Co. Ltd. now owns 1,109 shares of the medical equipment provider’s stock worth $75,000 after acquiring an additional 292 shares during the period. Institutional investors and hedge funds own 99.06% of the company’s stock.

Lantheus Trading Up 0.1%

LNTH stock opened at $103.92 on Friday. Lantheus Holdings, Inc. has a 1-year low of $47.25 and a 1-year high of $107.99. The company has a current ratio of 2.83, a quick ratio of 2.64 and a debt-to-equity ratio of 0.47. The business’s 50 day moving average is $93.37 and its 200-day moving average is $78.24. The firm has a market cap of $6.77 billion, a P/E ratio of 25.04 and a beta of -0.03.

Lantheus (NASDAQ:LNTH) last announced its quarterly earnings results on Thursday, May 7th. The medical equipment provider reported $1.46 EPS for the quarter, beating the consensus estimate of $1.25 by $0.21. Lantheus had a return on equity of 29.32% and a net margin of 18.05%.The business had revenue of $377.33 million for the quarter, compared to analyst estimates of $354.48 million. During the same quarter in the previous year, the firm earned $1.53 EPS. Lantheus’s quarterly revenue was up 1.2% on a year-over-year basis. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. Equities analysts anticipate that Lantheus Holdings, Inc. will post 4.39 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on LNTH shares. B. Riley Financial reissued a “buy” rating on shares of Lantheus in a report on Friday, May 1st. William Blair reaffirmed an “outperform” rating on shares of Lantheus in a research report on Tuesday, March 17th. JonesTrading downgraded shares of Lantheus from a “buy” rating to a “hold” rating in a research note on Friday, February 27th. Citigroup reissued an “outperform” rating on shares of Lantheus in a report on Friday, May 8th. Finally, Truist Financial restated a “buy” rating and issued a $115.00 price objective (up from $98.00) on shares of Lantheus in a research note on Monday, May 11th. Eight analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat, Lantheus has an average rating of “Moderate Buy” and a consensus target price of $101.86.

About Lantheus

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.